<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672434</url>
  </required_header>
  <id_info>
    <org_study_id>Sym024-01</org_study_id>
    <nct_id>NCT04672434</nct_id>
  </id_info>
  <brief_title>Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies</brief_title>
  <official_title>A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination With Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Symphogen A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Symphogen A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy&#xD;
      and in combination with Sym021 in patients with solid tumor malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 of this study will assess the safety and tolerability to establish the maximum&#xD;
      tolerated dose (MTD) (or the maximum administered dose [MAD]) and/or the selected dose(s) of&#xD;
      Sym024 in patients with solid tumor malignancies.&#xD;
&#xD;
      Part 2 of this study will assess the safety and tolerability to establish the MTD (or the&#xD;
      MAD) and/or the selected dose(s) of Sym024 when administered in combination with Sym021 in&#xD;
      patients with solid tumor malignancies.&#xD;
&#xD;
      Part 3 of this study will assess the safety of Sym024 when administered alone or in&#xD;
      combination with Sym021 in expanded cohorts of patients with solid tumor malignancies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: To evaluate the incidence, severity and relationship of (S)AEs to establish the MTD/MAD of Sym024 monotherapy.</measure>
    <time_frame>28 days</time_frame>
    <description>Assess the safety and tolerability of Sym024 monotherapy on a Q2W schedule (every two weeks). Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: To evaluate the incidence, severity and relationship of (S)AEs to establish MTD/MAD of Sym024 in combination with Sym021.</measure>
    <time_frame>28 days</time_frame>
    <description>Assess the safety and tolerability of the sequential escalating doses of Sym024 in combination with Sym021 on a Q2W schedule. Assessment based on the occurrence of AEs meeting DLT criteria measured during Cycle 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part III: To evaluate the incidence, severity and relationship of (S)AEs to further assess safety of Sym024 when administered alone or in combination with Sym021.</measure>
    <time_frame>12 months</time_frame>
    <description>Assess the safety and tolerability of Sym024 and/or Sym021+Sym024 on a Q2W schedule. Assessment based on the occurrence of AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the immunogenicity of Sym024 as a single agent and in combination with Sym024</measure>
    <time_frame>24 months</time_frame>
    <description>Serum sampling to assess the potential for anti-drug antibody (ADA) formation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of objective response (OR) or stable disease (SD)</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) and Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP) of disease</measure>
    <time_frame>24 months</time_frame>
    <description>Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in a dosing interval (AUC)</measure>
    <time_frame>24 months</time_frame>
    <description>Will be estimated using non-compartmental methods and actual timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>24 months</time_frame>
    <description>Will be derived from observed data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (Tmax)</measure>
    <time_frame>24 months</time_frame>
    <description>Will be derived from observed data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Ctrough)</measure>
    <time_frame>24 months</time_frame>
    <description>Will be derived from observed data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life (T½)</measure>
    <time_frame>24 months</time_frame>
    <description>Will be estimated using non-compartmental methods and actual timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL)</measure>
    <time_frame>24 months</time_frame>
    <description>Will be estimated using non-compartmental methods and actual timepoints</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Sym024 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I, Sym024 monotherapy dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym024 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I, Sym024 monotherapy dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym024 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I, Sym024 monotherapy dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym024 Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I, Sym024 monotherapy dose level 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym024 Dose Level -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I, Sym024 monotherapy dose level -1. Evaluate only if needed based on tolerability</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym021+Sym024 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part II, Sym021 in combination with dose level 2 of Sym024</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym021+Sym024 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part II, Sym021 in combination with dose level 3 of Sym024</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym021+Sym024 Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part II, Sym021 in combination with dose level 4 of Sym024</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sym021+Sym024 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part II, Sym021 in combination with dose level 1 of Sym024. Evaluate only if needed based on tolerability</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Sym021 (+Sym024)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part III, dose expansion Sym024 and/or Sym021+Sym024</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sym021</intervention_name>
    <description>Sym021 is a humanized anti-PD-1 antibody.</description>
    <arm_group_label>Dose Expansion Sym021 (+Sym024)</arm_group_label>
    <arm_group_label>Sym021+Sym024 Dose Level 1</arm_group_label>
    <arm_group_label>Sym021+Sym024 Dose Level 2</arm_group_label>
    <arm_group_label>Sym021+Sym024 Dose Level 3</arm_group_label>
    <arm_group_label>Sym021+Sym024 Dose Level 4</arm_group_label>
    <other_name>Anti-PD-1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sym024</intervention_name>
    <description>Sym024 is an anti-CD73 antibody.</description>
    <arm_group_label>Dose Expansion Sym021 (+Sym024)</arm_group_label>
    <arm_group_label>Sym021+Sym024 Dose Level 1</arm_group_label>
    <arm_group_label>Sym021+Sym024 Dose Level 2</arm_group_label>
    <arm_group_label>Sym021+Sym024 Dose Level 3</arm_group_label>
    <arm_group_label>Sym021+Sym024 Dose Level 4</arm_group_label>
    <arm_group_label>Sym024 Dose Level -1</arm_group_label>
    <arm_group_label>Sym024 Dose Level 1</arm_group_label>
    <arm_group_label>Sym024 Dose Level 2</arm_group_label>
    <arm_group_label>Sym024 Dose Level 3</arm_group_label>
    <arm_group_label>Sym024 Dose Level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients, ≥18 years.&#xD;
&#xD;
          -  Documented (histologically or cytologically proven), locally advanced or metastatic&#xD;
             solid tumor malignancy (must be one of the following):&#xD;
&#xD;
               1. Squamous cell carcinoma of the head and neck&#xD;
&#xD;
               2. Non-small-cell lung carcinoma-adenocarcinoma histology subtype&#xD;
&#xD;
               3. Pancreatic ductal adenocarcinoma&#xD;
&#xD;
               4. Cholangiocarcinoma&#xD;
&#xD;
               5. Colorectal carcinoma (microsatellite stable [MSS] and microsatellite&#xD;
                  instability-high [MSI-H] phenotypes)&#xD;
&#xD;
               6. Gastric carcinoma (includes gastroesophageal carcinoma)&#xD;
&#xD;
               7. Esophageal carcinoma (includes squamous cell and adenocarcinoma)&#xD;
&#xD;
               8. Mesothelioma (pleural and peritoneal)&#xD;
&#xD;
          -  Malignancy that is not currently amenable to surgical intervention due to either&#xD;
             medical contraindications or non-resectability of the tumor.&#xD;
&#xD;
          -  Measurable disease according to RECIST v1.1.&#xD;
&#xD;
          -  Refractory to or intolerant of existing therapy(ies) known to provide clinical&#xD;
             benefit.&#xD;
&#xD;
          -  Agreeing to mandatory tumor tissue biopsies (2 total).&#xD;
&#xD;
          -  ECOG PS of 0 or 1.&#xD;
&#xD;
          -  Adequate organ function as indicated by the following laboratory values.&#xD;
&#xD;
          -  Adequate contraception required as appropriate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Central nervous system (CNS) malignancies.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease or condition.&#xD;
&#xD;
          -  Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism within 4&#xD;
             weeks prior to the first dose of study drug(s).&#xD;
&#xD;
          -  Active uncontrolled bleeding or a known bleeding diathesis.&#xD;
&#xD;
          -  Significant ocular disease or condition.&#xD;
&#xD;
          -  Significant pulmonary disease or condition.&#xD;
&#xD;
          -  Current or recent (within 6 months) significant gastrointestinal disease or condition.&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease.&#xD;
&#xD;
          -  History of organ transplantation (i.e., stem cell or solid organ transplant).&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) or known active infection with&#xD;
             hepatitis B virus (HBV) or hepatitis C virus (HCV).&#xD;
&#xD;
          -  Any other serious/active/uncontrolled infection.&#xD;
&#xD;
          -  History of significant toxicities associated with previous administration of immune&#xD;
             checkpoint inhibitors.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to any of the excipients of formulated study drug.&#xD;
&#xD;
          -  Unresolved &gt;Grade 1 toxicity associated with any prior antineoplastic therapy.&#xD;
&#xD;
          -  Inadequate recovery from any prior surgical procedure, or patients having undergone&#xD;
             any major surgical procedure within 4 weeks prior to the first dose of study drug(s).&#xD;
&#xD;
          -  Any other serious, life-threatening, or unstable preexisting medical condition (aside&#xD;
             from the underlying malignancy).&#xD;
&#xD;
        Therapeutic Exclusions&#xD;
&#xD;
          -  Prior therapy with Sym024 or other inhibitors of CD73, CD39 or adenosine receptors&#xD;
             ADORA2A, ADORA2B.&#xD;
&#xD;
          -  Part II and Part III, prior anti-PD-(L)1 therapy, except for indications where it is&#xD;
             approved.&#xD;
&#xD;
          -  Any antineoplastic agent for the primary malignancy (standard or investigational)&#xD;
             within 4 weeks or 5 elimination half-lives.&#xD;
&#xD;
          -  Any other investigational treatments within 2 weeks prior to the first dose of study&#xD;
             drug(s).&#xD;
&#xD;
          -  Radiotherapy, with exceptions.&#xD;
&#xD;
          -  Live vaccines against infectious diseases 4 weeks prior to the first dose of study&#xD;
             drug(s).&#xD;
&#xD;
          -  Immunosuppressive or systemic glucocorticoids therapy (&gt;10 mg daily prednisone or&#xD;
             equivalent) within 2 weeks prior to the first dose of study drug(s), with exceptions.&#xD;
&#xD;
          -  Prophylactic use of hematopoietic growth factors within 1 week prior to the first dose&#xD;
             of study drug(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>N. Lakhani, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>START Midwest, USA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>U. Hansen</last_name>
    <phone>+45 45265050</phone>
    <email>info@symphogen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49545</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nehal Lakhani, MD PhD</last_name>
      <phone>616-954-5554</phone>
      <email>nehal.lakhani@startmidwest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordi Rodon, MD PhD</last_name>
      <phone>713-792-5603</phone>
      <email>jrodon@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Sommerhalder, MD</last_name>
      <phone>210-580-9500</phone>
      <email>dsommerhalder@nextoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Spreafico, MD PhD</last_name>
      <phone>416-946-3308</phone>
      <email>anna.spreafico@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 7, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally advanced/unresectable</keyword>
  <keyword>Metastatic solid tumor</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PD1</keyword>
  <keyword>CD73</keyword>
  <keyword>Squamous cell carcinoma of the head and neck (SCCHN)</keyword>
  <keyword>Non-small-cell lung carcinoma-adenocarcinoma histology subtype (NSCLC-Adeno)</keyword>
  <keyword>Pancreatic ductal adenocarcinoma (PDAC)</keyword>
  <keyword>Cholangiocarcinoma (CCA)</keyword>
  <keyword>Colorectal carcinoma (CRC)</keyword>
  <keyword>Gastric carcinoma (GC)</keyword>
  <keyword>Esophageal carcinoma (EsoCA)</keyword>
  <keyword>Mesothelioma (Meso)</keyword>
  <keyword>Sym021</keyword>
  <keyword>Sym024</keyword>
  <keyword>Head and neck squamous cell carcinoma (HNSCC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

